Literature DB >> 24315973

Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.

Masashi Machii1, Hiroshi Satoh2, Katsunori Shiraki1, Masao Saotome1, Tsuyoshi Urushida1, Hideki Katoh1, Yasuo Takehara3, Harumi Sakahara3, Hayato Ohtani4, Yasushi Wakabayashi4, Hiroshi Ukigai5, Kei Tawarahara5, Hideharu Hayashi1.   

Abstract

BACKGROUND: The prognostic implications of late gadolinium enhancement (LGE) have been evaluated in ischemic and non-ischemic cardiomyopathies. The present study analyzed LGE distribution in patients with end-stage hypertrophic cardiomyopathy (ES-HCM) and with dilated cardiomyopathy (DCM), and tried to identify high risk patients in DCM.
METHODS: Eleven patients with ES-HCM and 72 with DCM underwent cine- and LGE-cardiac magnetic resonance and ultrasound cardiography. The patient outcome was analyzed retrospectively for 5years of follow-up.
RESULTS: LGE distributed mainly in the inter-ventricular septum, but spread more diffusely into other left ventricular segments in patients with ES-HCM and in a certain part of patients with DCM. Thus, patients with DCM can be divided into three groups according to LGE distribution; no LGE (n=24), localized LGE (localized at septum, n=36), and extensive LGE (spread into other segments, n=12). Reverse remodeling occurred after treatment in patients with no LGE and with localized LGE, but did not in patients with extensive LGE and with ES-HCM. The event-free survival rate for composite outcome (cardiac death, hospitalization for decompensated heart failure or ventricular arrhythmias) was lowest in patients with extensive LGE (92%, 74% and 42% in no LGE, localized LGE, and extensive LGE, p=0.02 vs. no LGE), and was comparable to that in patients with ES-HCM (42%).
CONCLUSIONS: In DCM, patients with extensive LGE showed no functional recovery and the lowest event-free survival rate that were comparable to patients with ES-HCM. The analysis of LGE distribution may be valuable to predict reverse remodeling and to identify high-risk patients.
© 2013.

Entities:  

Keywords:  Cardiac magnetic resonance; Dilated cardiomyopathy; End-stage hypertrophic cardiomyopathy; Late gadolinium enhancement; Outcomes; Reverse remodeling

Mesh:

Substances:

Year:  2013        PMID: 24315973     DOI: 10.1016/j.mri.2013.10.011

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  10 in total

1.  Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat.

Authors:  Hung-I Lu; Meng-Shen Tong; Kuan-Hung Chen; Fan-Yen Lee; John Y Chiang; Sheng-Ying Chung; Pei-Hsun Sung; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 2.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

3.  LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results.

Authors:  Sainan Cheng; Mengjie Fang; Chen Cui; Xiuyu Chen; Gang Yin; Sanjay K Prasad; Di Dong; Jie Tian; Shihua Zhao
Journal:  Eur Radiol       Date:  2018-05-04       Impact factor: 5.315

4.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.

Authors:  Sainan Cheng; Yeon Hyeon Choe; Hideki Ota; Chen Cui; Gang Yin; Minjie Lu; Lu Li; Xiuyu Chen; Sanjay K Prasad; Shihua Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2017-10-25       Impact factor: 2.357

5.  Role of Cardiac MRI in the Assessment of Cardiomyopathy.

Authors:  Róisín B Morgan; Raymond Kwong
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11

Review 6.  Intra-cardiac distribution of late gadolinium enhancement in cardiac sarcoidosis and dilated cardiomyopathy.

Authors:  Makoto Sano; Hiroshi Satoh; Kenichiro Suwa; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi; Takeji Saitoh
Journal:  World J Cardiol       Date:  2016-09-26

7.  Prognostic value of late gadolinium enhancement in cardiac MRI of non-ischemic dilated cardiomyopathy patients.

Authors:  Dibya Ranjan Behera; Ajit Kumar V K; Narayanan Namboodiri K K; Sivasankaran S; Krishna Kumar Mohanan Nair; Sanjay G; Kapilamoorthy T R; Arun Gopalakrishnan; Harikrishnan S
Journal:  Indian Heart J       Date:  2020-07-02

8.  Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction.

Authors:  Nobuichiro Yagi; Osamu Seguchi; Hiroki Mochizuki; Kensuke Kuroda; Seiko Nakajima; Takuya Watanabe; Masanobu Yanase; Naoki Tadokoro; Satsuki Fukushima; Tomoyuki Fujita; Norihide Fukushima
Journal:  ESC Heart Fail       Date:  2021-10-27

Review 9.  Non-ischemic dilated cardiomyopathy and cardiac fibrosis.

Authors:  Bianca Olivia Cojan-Minzat; Alexandru Zlibut; Lucia Agoston-Coldea
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

10.  Overlapping Phenotypes and Degree of Ventricular Dilatation Are Associated with Severity of Systolic Impairment and Late Gadolinium Enhancement in Non-Ischemic Cardiomyopathies.

Authors:  Marko Boban; Vladimir Pesa; Viktor Persic; Marinko Zulj; Ivan Malcic; Natko Beck; Aleksandar Vcev
Journal:  Med Sci Monit       Date:  2018-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.